Novartis AG ADR
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $14,417,876 | $13,524,000 | $13,334,986 | $14,358,000 |
Gross Profit | 10,737,355 | 10,065,000 | 9,793,255 | 10,819,000 |
EBITDA | 5,936,066 | 5,410,000 | 5,072,614 | 5,841,000 |
EBIT | 4,735,243 | 4,182,000 | 3,521,732 | 4,477,000 |
Net Income | 3,266,237 | 3,156,000 | 2,408,817 | 3,928,000 |
Net Change In Cash | 14,417,876 | 13,524,000 | 13,334,986 | 14,358,000 |
Free Cash Flow | 5,566,988 | 2,869,000 | 1,642,801 | 5,740,000 |
Cash | 7,616,031 | 6,877,000 | 11,435,020 | 9,556,000 |
Basic Shares | 1,914,000 | 1,916,000 | 1,929,000 | 1,940,000 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $54,811,252 | $51,722,000 | $46,660,000 | $43,461,000 |
Gross Profit | 41,121,506 | 38,895,000 | 34,188,000 | 31,879,000 |
EBITDA | 22,987,115 | 20,715,000 | 18,255,000 | 14,682,000 |
EBIT | 17,634,846 | 14,646,000 | 9,978,000 | 7,977,000 |
Net Income | 14,055,610 | 11,941,000 | 14,850,000 | 6,955,000 |
Net Change In Cash | 54,811,252 | 51,722,000 | 46,660,000 | 43,461,000 |
Free Cash Flow | 17,686,107 | 13,805,000 | 11,705,000 | 11,565,000 |
Cash | 11,435,020 | 11,459,000 | 13,393,000 | 7,517,000 |
Basic Shares | 1,955,000 | 2,035,000 | 2,092,000 | 2,197,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $2.41 |
2026-03-31 | $1.65 |
2025-12-31 | $2.03 |
2025-09-30 | $2.25 |